Table 16All-cause mortality (# subjects / # randomized) for all other standard treatment trials

StudyVancomycinMetronidazoleNitazoxanideFidaxomicinBacitracinPlacebo
Musher, 200969Overall mortality was 4% (2/49 subjects) (treatment groups not noted)
Lagrotteria, 2006711/20 (5)
6/19 (32) + Rif
Musher, 2006721+/44*3+/98*
Fekety, 1989751/28 HD
1/28 LD
Dudley, 1986740/311/31 (3)
Young, 1985770/210/21
Keighley, 1978780 “colitis”/120 “colitis”/12
Louie, 20117921/323 (7)16/300 (5)
*

A total of 13 deaths (9 percent) occurred, but only the 4 deaths above were denoted by treatment arm.

Numbers based on safety population.

From: Results

Cover of Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium difficile Infection
Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium difficile Infection [Internet].
Comparative Effectiveness Reviews, No. 31.
Butler M, Bliss D, Drekonja D, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.